Summary basis of decision for Xermelo

Health Canada Summary Basis of Decision 2019-01-25. Xermelo, telotristat ethyl (as telotristat etiprate), 250 mg, tablet, Ipsen Biopharmaceuticals Canada Inc.. Submission Control Number 208730.